TESARO Inc (NASDAQ:TSRO) was the recipient of unusually large options trading activity on Friday. Stock traders purchased 4,766 call options on the stock. This represents an increase of approximately 1,698% compared to the typical volume of 265 call options.
Shares of TESARO (TSRO) opened at $80.58 on Monday. TESARO has a 52-week low of $77.20 and a 52-week high of $192.94. The company has a quick ratio of 4.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.34.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.69. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The business had revenue of $142.77 million during the quarter, compared to the consensus estimate of $130.57 million. During the same quarter last year, the firm posted ($1.72) EPS. TESARO’s revenue was up 740.3% compared to the same quarter last year. analysts expect that TESARO will post -8.17 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Exane Derivatives purchased a new position in TESARO during the 3rd quarter worth $106,000. Nordea Investment Management AB purchased a new position in TESARO during the 2nd quarter worth $167,000. Oppenheimer Asset Management Inc. boosted its holdings in TESARO by 3,042.6% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock worth $206,000 after acquiring an additional 1,430 shares during the last quarter. Toronto Dominion Bank boosted its holdings in TESARO by 244.6% during the 3rd quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock worth $206,000 after acquiring an additional 1,130 shares during the last quarter. Finally, BB&T Securities LLC purchased a new position in TESARO during the 2nd quarter worth $222,000.
Several analysts have recently weighed in on TSRO shares. Citigroup reiterated a “buy” rating and issued a $216.00 price objective on shares of TESARO in a research note on Monday, September 11th. Oppenheimer reiterated a “buy” rating and issued a $199.00 price objective on shares of TESARO in a research note on Sunday, September 10th. Cann reiterated a “buy” rating and issued a $199.00 price objective on shares of TESARO in a research note on Friday, September 8th. SunTrust Banks reiterated a “buy” rating and issued a $235.00 price objective on shares of TESARO in a research note on Sunday, August 20th. Finally, HC Wainwright started coverage on shares of TESARO in a research note on Thursday, October 12th. They issued a “buy” rating and a $158.00 price objective for the company. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. TESARO currently has a consensus rating of “Buy” and a consensus target price of $159.39.
WARNING: This piece was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://sportsperspectives.com/2017/12/18/stock-traders-purchase-high-volume-of-tesaro-call-options-tsro.html.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.